Abstract
Serotonin was the first neurotransmitter believed to be involved in cephalic pain transfer forward to the cortex, but the precise mechanism was confirmed only after sumatriptan, a 5-HT1B/1D high affinity agonist, was introduced in the acute treatment of migraine. Although very efficient for migraine relief, activation of 5-HT1B receptor may also cause vasoconstriction outside brain, within the heart arteries for example. Unlike 5-HT1B, the 5-HT1D receptor is not located in vascular tissues but exclusively within neuronal, but high affinity agonists for 5-HT1D failed to prove clinical significance in randomized trials. The recent clone of 5-HT1F receptor together with data showing that sumatriptan exerts high affinity for this receptor subtype generated high expectations. Potent agonists for 5-HT1F receptors were effective in animal models for migraine and later clinical trials showed efficacy even in humans, introducing the first line future anti-migraine drugs. Apart from 5-HT1F, another new cloned 5-HT subtype receptor, the 5-HT7 also attracts attention. Recently developed and clinically tested selective 5HT7 antagonists SB-269970-A and SB-656104-A suggest that the receptor may play a role in other CNS disorders including anxiety and cognitive disturbances, suggesting a potential role for the migraine prophylaxis. These data and speculations are discussed in details in this paper with special references.
Keywords: 5-HT1D receptors, mRNA, anti-migraine drugs, 5-HT1B, LY334370
CNS & Neurological Disorders - Drug Targets
Title: 5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines
Volume: 6 Issue: 4
Author(s): Reto M. Agosti
Affiliation:
Keywords: 5-HT1D receptors, mRNA, anti-migraine drugs, 5-HT1B, LY334370
Abstract: Serotonin was the first neurotransmitter believed to be involved in cephalic pain transfer forward to the cortex, but the precise mechanism was confirmed only after sumatriptan, a 5-HT1B/1D high affinity agonist, was introduced in the acute treatment of migraine. Although very efficient for migraine relief, activation of 5-HT1B receptor may also cause vasoconstriction outside brain, within the heart arteries for example. Unlike 5-HT1B, the 5-HT1D receptor is not located in vascular tissues but exclusively within neuronal, but high affinity agonists for 5-HT1D failed to prove clinical significance in randomized trials. The recent clone of 5-HT1F receptor together with data showing that sumatriptan exerts high affinity for this receptor subtype generated high expectations. Potent agonists for 5-HT1F receptors were effective in animal models for migraine and later clinical trials showed efficacy even in humans, introducing the first line future anti-migraine drugs. Apart from 5-HT1F, another new cloned 5-HT subtype receptor, the 5-HT7 also attracts attention. Recently developed and clinically tested selective 5HT7 antagonists SB-269970-A and SB-656104-A suggest that the receptor may play a role in other CNS disorders including anxiety and cognitive disturbances, suggesting a potential role for the migraine prophylaxis. These data and speculations are discussed in details in this paper with special references.
Export Options
About this article
Cite this article as:
Reto M. Agosti , 5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines, CNS & Neurological Disorders - Drug Targets 2007; 6 (4) . https://dx.doi.org/10.2174/187152707781387242
DOI https://dx.doi.org/10.2174/187152707781387242 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses
Current Pharmaceutical Biotechnology Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole
Current Drug Metabolism Ideational Fluency in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Modern 3D Printing Technologies: Future Trends and Developments
Recent Patents on Engineering Tuberculosis - Present Medication and Therapeutic Prospects
Current Medicinal Chemistry Structure, Biological Properties and Applications of Marine-derived Polysaccharides
Current Organic Chemistry Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Cannabinoid Signaling in Glial Cells in Health and Disease
Current Neuropharmacology Subdural Pharmacotherapy for the Treatment of Intractable Focal Neocortical Epilepsy
Drug Delivery Letters The Application of X-ray, NMR, and Molecular Modeling in the Design of MMP Inhibitors
Current Topics in Medicinal Chemistry Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Radiolabeled Organism-Specific Antibodies for Diagnosis and Therapy of Infections
Current Medical Imaging PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies
Medicinal Chemistry Recent Advances in Peptide-Based Approaches for Cancer Treatment
Current Medicinal Chemistry MRI in Normal Myelination: A Pictorial Review
Current Pediatric Reviews